Skip to main content

Effect and Mode of Action of N4-Behenoyl-β-D-Arabinofuranosylcytosine

  • Chapter
New Anticancer Drugs

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 70))

Summary

N 4-Behenoyl-β-D-arabinofuranosylcytosine (behenoyl ara-C, NSC 239336) enhanced che-motherapeutic activity against L1210 murine leukemia as compared with 1-β-D-arabino-furanosylcytosine (ara-C). Behenoyl ara-C was resistant to deamination by cytidine deaminase, which was supposed to be liable for inactivating ara-C in vivo. Behenoyl ara-C exerted chemotherapeutic activity when administered before implantation of leukemic cells, suggesting prolonged circulation in the body fluid. These two findings indicate that the resistance to the enzymatic deamination and hydrophobicity endowed by behenic residue were responsible for the enhanced chemotherapeutic activity of behenoyl ara-C. This idea was supported by the finding that ara-C encapsulated in liposome enhanced chemotherapeutic activity.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aoshima, M., Tsukagoshi, S., Sakurai, Y., Ohishi, J., Ishida, T., Kobayashi, H.: Antitumor activities of newly synthesized N 4-acyl-1-β-D-arabinofuranosylcytosine. Cancer Res. 37, 2481 (1977)

    PubMed  CAS  Google Scholar 

  2. Gregoriadis, G.: Targeting of drugs. Nature 265, 407 (1977)

    Article  PubMed  CAS  Google Scholar 

  3. Kataoka, T., Williamson, J. R., Kinsky, S. C.: Release of maeromolecular markers (enzymes) from liposomes treated with antibody and complement. Biochim. Biophys. Acta 298, 158 (1973)

    CAS  Google Scholar 

  4. Kobayashi, T., Kataoka, T., Tsukagoshi, S., Sakurai, Y.: Enhancement of anti-tumor activity of 1-β-D-arabinofuranosylcytosine by encapsulation in liposomes. Int. J. Cancer 20, 581 (1977)

    Article  PubMed  CAS  Google Scholar 

  5. Mayhew, E., Papahadjopoulos, D., Rustum, Y. M., Dave, C.: Inhibition of tumor cell growth in vitro and in vivo by 1-β-D-arabinofuranosylcytosine entrapped within phospholipid vesicles. Cancer Res. 36, 4406 (1976)

    PubMed  CAS  Google Scholar 

  6. Sessa, G., Weissman, G.: Incorporation of lysosyme into liposomes. J. Biol. Chem. 245, 3295 (1970)

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 1980 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Kataoka, T., Sakurai, Y. (1980). Effect and Mode of Action of N4-Behenoyl-β-D-Arabinofuranosylcytosine. In: Carter, S.K., Sakurai, Y. (eds) New Anticancer Drugs. Recent Results in Cancer Research, vol 70. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-81392-4_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-81392-4_15

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-81394-8

  • Online ISBN: 978-3-642-81392-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics